

PATENT

Case Docket No. LOMACEN.015C5

Date: November 12, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : William J. Wechter
Appl. No. : 10/661,336
Filed : September 12, 2003
For : USE OF γ -TOCOPHEROL AND
ITS OXIDATIVE
METABOLITE LLU- α IN THE
TREATMENT OF DISEASE
Examiner : Unassigned
Group Art Unit : Unassigned

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 12, 2003

(Date)


Eric S. Furman, Ph.D., Reg. No. 45,664


TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) PTO Form 1449 in four pages with fifty-six (56) references, four (4) of which are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Wechter, William J.)	Group Art Unit Unassigned
)	
App. No.	:	10/661,336)	
)	
Filed	:	September 12, 2003)	
)	
For	:	USE OF γ -TOCOPHEROL AND)	
		ITS OXIDATIVE METABOLITE)	
		LLU- α IN THE TREATMENT)	
		OF DISEASE)	
)	
Examiner	:	Unassigned)	
)	
)	

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing fifty-six (56) references. The four (4) references listed on sheet 1 are enclosed. The remaining fifty-two (52) references on sheet 2, 3, and 4 were previously listed in an Information Disclosure Statement for Application No. 10/372,510, filed on March 26, 2003. The present patent application is a continuation application of Application No. 10/372,510 and is relied upon for an earlier filing date under 35 U.S.C. § 120. Therefore, according to paragraph (d) of 37 C.F.R. § 1.98, no copies of the references are enclosed.


Appl. No. : 10/661,336
Filed : September 12, 2003

This Information Disclosure Statement is being filed within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4). If a fee is determined necessary for the filing of this paper, please charge Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Nov. 12, 2003

By: 
Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
2040 Main Street
Fourteenth Floor
Irvine, CA 92614
(619) 235-8550

S:\DOCS\ESF\ESF-7299.DOC
111103



FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
LOMACEN.015C5APPLICATION NO.
10/661,336INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
William J. WechterFILING DATE
September 12, 2003

GROUP

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,144,325	03/13/79	Voyt	424	59	
	2.	6,410,589	06/25/02	Wechter	514	548	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	3.	0 350 913	01/17/90	EPO				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	4.	Isselbacher, et al., Ed's, Harrison's Principles of Internal Medicine, 13 th ed., Vol. 2, McGraw-Hill, New York, 1994.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	



FORM PTO-122P

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
LOMACEN.015C5APPLICATION NO.
10/661,336INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
William J. WechterFILING DATE
September 12, 2003

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,321,270	03/23/82	Sundeen	424	267	
	2.	4,914,197	04/03/90	Yamamoto et al.	536	117	
	3.	5,139,796	08/18/92	Barkalow et al.	426	3	
	4.	5,200,214	04/06/93	Barkalow et al.	426	3	
	5.	5,270,060	12/14/93	Foster et al.	426	3	
	6.	5,739,156	04/14/98	Bissett	514	458	
	7.	6,048,891	04/11/00	Wechter	514	456	
	8.	6,242,479	06/05/01	Wechter	514	456	
	9.	6,426,362	07/30/02	Miller et al.	514	458	
	10.	2002/0040053	04/04/02	Kondo et al.	514	456	
	11.	2002/0132845	09/19/02	Miller et al.	514	458	
	12.	2002/0143049	10/03/02	Miller et al.	514	458	
	13.	2003/0013656	01/16/03	Wang et al.	514	17	
	14.	2003/0013657	01/16/03	Wang et al.	514	17	
	15.	2003/0013846	01/16/03	Wang et al.	530	330	
	16.	2003/0013847	01/16/03	Wang et al.	530	330	
	17.	2003/0022818	01/30/03	Wang et al.	514	6	


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	18.	0 326 987 A2		EPO				
	19.	0 413 668 A2		EPO				
	20.	WO 96/05191		PCT				

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.




FORM PTO-149 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. LOMACEN.015C5	APPLICATION NO. 10/661,336
	APPLICANT William J. Wechter	
	FILING DATE September 12, 2003	GROUP

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	21.	WO 96/19215		PCT				


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	22.	Beharka, et al., "Vitamin E Status and Immune Function," Methods in Enzymology, Vol. 282, pp. 247-263, 1997.
	23.	Benaksas, et al., Life Sciences, 52:1045-54 (1993)
	24.	Bottje et al., "Effect of Dietary dl-alpha-Tocopherol on tissue alpha- and Gamma- Tocopherol and Pulmonary Hypertension Syndrome (Ascities in Broilers," Poultry Science, 76:1506-12, Abstract Only (1997)
	25.	Burnett, et al., "Mechanisms of Phytochemical Inhibition . . .," American Chemical Society Symposium Series, pp. 45-58, 1998.
	26.	Campo, et al., <i>Free Radical Biology and Medicine</i> , "Reduction of Myocardial Infarct Size in rat by IRFI-048, a selective analogue of Vitamin E", Vol. 16, pp.427-435 (1994)
	27.	Campo, et al., <i>Pharmacology</i> , "Protective Effects of IRF-016, a New Antioxidant Agent, in Myocardial Damage, following coronary artery occlusion and reperfusion in the rat", 48:157-166 (1994)
	28.	Campo, et al., <i>Research Comm. in Chem. Pathology and Pharmacology</i> , "IRFI-016, a new radical scavenger, limits ischemic damage following coronary artery occlusion in rats", Vol. 76, No., pp.287-303, (1992)
	29.	Christen et al., "γ-Tocopheral Traps Mutagenic Electrophiles such as NO _x and Complements alpha-Tocopheral: Physiological Implications," Proc. Natl. Acad. Sci., USA, 94(7):3217-22 (1997)
	30.	Elson, Charles E., "Impact of Palm Oil on Experimental Carcinogenesis," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 39, pp. 533-45 (1993)
	31.	Frei & Ames, "Relative Importance of Vitamine E in Antiperoxidative Defenses in Human Blood Plasma and Low-Density Lipoprotein (LDL)," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 10, pp. 131-39 (1993)
	32.	Germano, Carl, http://www.solgar.com/nutrition_library/articles/tocotrienols.html , Posted 11/27/1997, 4 pgs., "Tocotrienols in Health & Disease: A Novel Antioxidant in the Treatment of Hypercholesterolemia and Cancer."
	33.	Kantoci et al., "Endogenous Natriuretic Factors 6: The Stereochemistry of a Natriuretic γ-Tocopherol Metabolite LLU-α," Journal of Pharmacology and Experimental Therapeutics, 282(2):648-656 (1997)
	34.	Life Extension Foundation, http://lef.org/prod_desc/item564.html , (1995-1999), 2 pgs., "Gamma E Tocopherol Formula."

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

	FORM PTO-1448 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. LOMACEN.015C5	APPLICATION NO. 10/661,336
	APPLICANT William J. Wechter		
	FILING DATE September 12, 2003	GROUP	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	35. Life Extension Foundation, http://lef.org/cgi-local/shop.pl/page=feb98_newproduct.html , (1995-1999), 3 pgs., "Not all Vitamin E is Created Equal."
	36. McLaughlin & Weihrauch, "Vitamin E Content of Foods," Journal of the American Dietetic Association, 75:6547-665 (1979)
	37. Meydani, Mohsen, "Vitamin E," The Lancet, 345:170-175 (1995)
	38. Meydani, S. & R. Tengerdy, "Vitamin E and Immune Response," Vitamine E in Health and Disease, Packer & Fuchs eds, Chapter 40, pp. 549-561 (1993)
	39. Murray, David E. et al., "Endogenous Natriuretic Factors 7: Biospecificity of a Natriuretic γ -Tocopherol Metabolite LLU- α^1 ," The Journal of Pharmacology and Experimental Therapeutics, Vol. 282, pp. 657-662 (1997)
	40. Nando.net & The Associated Press, http://www.nando.net/newsroom/ntn/health/033197/health12-4931.html , 1997, 2 pgs., "Too Much Vitamin E Can be Harmful."
	41. Odeleve, et al., "The Potential Role of Vitamin E in the Treatment of Immunologic Abnormalities During Acquired Immune Deficiency Syndrome," Database Medline, 1991.
	42. Packer et al., "Significance of Vitamin E for the Athlete," Vitamine E in Health and Disease, Packer & Fuchs eds, (1993) Chapter 34, pp. 465-71
	43. Richardson et al., "Adhesion of Human Platelets Inhibited by Vitamin E," Vitamine E in Health and Disease, Packer & Fuchs eds, 1993, Ch. 24, pp. 297-311.
	44. Shigenaga et al., "Inflammation and NO _x -induced Nitration: Assay for 3-nitrotyrosine by HPLC with Electrochemical Detection," Proc. Natl. Acad. Sci. USA, 94(7):3211-3216 (1997)
	45. Speek et al., "Vitamin E Composition of Some Speed Oils as Determined by High-Performance Liquid Chromatography with Fluorometric Detection," Journal of Food Science, 501:121-124 (1985)
	46. Stone, et al., "Tocopherols and the Etiology of Colon Cancer," Journal of the National Cancer Institute, Vol 89, pp. 1006-1014, 1997.
	47. The Merck Index, 11 th edition, published by Merck & Co., Inc. (NJ), 1989, citation 9418, pg. 1495.
	48. Wechter et al., "A New Endogenous Natriuretic Factor: LLU- α ," Proc. Natl. Acad. Sci. USA, 93:6002-6007 (1996)
	49. Weichet et al., "Studien in der Gruppe der Vitamine K und E vi. Über die Darstellung von 2, 5, 7, 8, - Tetramethyl-2-(β -Carboxy-Äthyl)-6-Hydroxychroman und Dessen Oxydationsprodukt," Collection Czechoslov. Chem. Commun., 24:1689-1694 (1959) No Translation
	50. Official Monographs, "Vitamin E," "Vitamin E Preparation," and "Vitamin E Capsules," USP 23, pp. 1631-1633
	51. "Myraid Genetics Plans to Launch the First Genetic Test for High Blood Pressure," Genetic Engineering News, pg. 27 (1997)
	52. Yarita, et al., "Supercritical Fluid Chromatographic Determination of Cholesterol and Cholesteryl Esters in Serum on ODS-Silica Gel Column," Journal of Chromatography A., Vol. 679, pp. 329-334, 1994.

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

 FORM PTO-148 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. LOMACEN.015C5	APPLICATION NO. 10/661,336
	APPLICANT William J. Wechter	
	FILING DATE September 12, 2003	GROUP

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S:\DOCS\IESF\ESF-7300.DOC
111103

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	